Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327909 · ClinicalTrials.gov registry record · NA
Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis
A NA study of Blood Pressure and ESRD, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 131
- Enrollment target
- 2
- Study locations
NCT03327909: Completed NA study of Blood Pressure and ESRD, sponsored by Stanford University.
NCT03327909 is a NA study of Blood Pressure and ESRD that has completed, run by Stanford University. The registered enrollment target is 131 participants, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03327909, a NA study of Blood Pressure and ESRD, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 131 participants
- Enrollment target
- 2
- Study locations
Study Summary
For patients with kidney failure requiring hemodialysis treatment, sometimes the blood pressure will drop too low during dialysis. In an effort to prevent that from occurring, patients are frequently told to skip doses of their blood pressure medications. However, whether this actually prevents blood pressure drops during dialysis, and whether it may cause more uncontrolled high blood pressure is unknown. TAKE-HOLD will study the effect of taking or holding blood pressure medication on blood pressure for patients on hemodialysis.
Primary Outcome
Number of participants with ≥30% of dialysis sessions with symptomatic or asymptomatic IDH.
Conditions Studied
Interventions
- BEHAVIORAL TAKE vs. HOLD
Study Locations (2)
California
- Satellite Health Care - Menlo Park
- Satellite Health Care - San Carlos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2019-12-14 |
| Phase | NA |
What the finished NCT03327909 record still lists
NCT03327909 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (54% lower).
The record links to 3 conditions, with Blood Pressure appearing as the primary indexed condition, and to 1 intervention - of which TAKE vs. HOLD is the first listed.
NCT03327909 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03327909 about?
NCT03327909 is a clinical study titled "Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis". For patients with kidney failure requiring hemodialysis treatment, sometimes the blood pressure will drop too low during dialysis. In an effort to prevent that from occurring, patients are frequently told to skip doses of their blood pressure medications. However, whether this actually prevents bloo...
What is the current status of trial NCT03327909?
This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2018-07-16. Estimated completion is 2019-12-14.
What conditions does trial NCT03327909 study?
This clinical trial studies the following conditions: Blood Pressure, ESRD, Hemodialysis Complication.
What interventions are being tested in trial NCT03327909?
The interventions under investigation include: TAKE vs. HOLD (BEHAVIORAL).
Who is sponsoring clinical trial NCT03327909?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03327909 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03327909's enrollment target sits among peer trials
131 31st of 101 higher than 71 of 101 other Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Cocooned Moms Study
RECRUITING · NA
-
The GUARDIAN Trial
RECRUITING · NA
-
The Venous Distension Reflex and Orthostatic Hypertension
RECRUITING · NA
-
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
RECRUITING · NA
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI